Kural 2004.

Methods	No participants had been receiving lipid‐lowering drug treatment; therefore no wash‐out period was required 6‐Week to 12‐week before‐and‐after trial
Participants	40 men and women from Turkey with dyslipidaemia aged 53 years (41‐65) Exclusion criteria: hypothyroidism, diabetes mellitus, nephrotic syndrome, renal insufficiency, hepatic dysfunction, cancer, immune disorder, uncontrolled HTN, smoking, CAD Baseline TC: 7.45 mmol/L (288 mg/dL) Baseline LDL‐C: 5.28 mmol/L (204 mg/dL) Baseline HDL‐C: 1.06 mmol/L (41 mg/dL) Baseline TG: 2.27 mmol/L (201 mg/dL)
Interventions	Atorvastatin 40 mg/d
Outcomes	Per cent change from baseline at 4 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 40 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 40 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 40 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	Low risk	The study appears to be free of other sources of bias